Biocomposites
Simon Greenhalgh has extensive work experience in finance and management roles. Simon is currently the Group Chief Financial Officer at Biocomposites. Prior to this, they were the Company Owner/Director of SG Business Consultants Limited. Simon has also worked as the Group Chief Financial Officer at Arlington Industries Group and the Group Finance Director at Gamma Global Group. In addition, they have held positions such as Chief Financial Officer at Gelert Limited, Group Finance Director at Confidential Group(s), Group Finance Director at Document Express, Group Finance Director at Rectella, and Group Finance Director at Syrius/Magnum Group(s). Throughout their career, Simon has been involved in various industries including manufacturing, distribution, IT, and retail. Simon has a strong track record of driving restructuring and turnaround initiatives, managing finance functions, and providing strategic leadership.
Simon Greenhalgh completed their education in a chronological order. From 1989 to 1993, they attended AAT (Association of Accounting Technicians) and obtained a degree in FMAAT (Full Member of the Association of Accounting Technicians) with a field of study in Accounting. From 1993 to 1996, they pursued ACCA (Association of Chartered Certified Accountants) and received a degree as a Chartered Accountant. Simultaneously, during the same period, they also studied at ATC (Accounting Training Center) / Financial Training, completing a degree in FCCA (Fellow of the Association of Chartered Certified Accountants) with a focus on Accounting and Finance.
This person is not in any offices
Biocomposites
Biocomposites is an international medical device company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue. Based in Keele, UK, it has global operations across Europe, USA, Canada, China and India. Biocomposites is a world leader in the development of innovative calcium compounds for surgical use. Its products target a broad spectrum of infection risks across a variety of specialities, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle and podiatry. Biocomposites products are now used in over 100,000 procedures per annum and sold in more than 40 countries around the world. Please visit biocomposites.com to learn more.